Author Index to Volume 47

Abi-Dargham A. See Krystal JH. See Laruelle M
Abi-Saab D. See D'Souza DC. See Krystal JH
Ackenheil M. See Schwarz MJ
Adalsteinsson E. See Winsberg ME
Adams MR. See Bethea CL
Adler LE. See Olincy A. See Waldo MC
Akil N, Edgar CL, Pierri JN, Casali S, Lewis DA. Decreased density of tyrosine hydroxylase–immunoreactive axons in the entorhinal cortex of schizophrenic subjects, 361
Akiskal H. See Coryell W
Altshuler LL. See McElroy SL
Amara SG. See Wong EHF
Amiaz R. See Grunhaus L
Anand A. See Berman RM
Ancoli-Israel S. See Jean-Louis G
Andresen B. See Klein C
Andreski P. See Breslau N
Ansved T. See Flyckt L
Armitage R. See Fulton MK
Armitage R, Emslie GJ, Hoffmann RF, Weinberg WA, Kowatch RA, Rintelmann J, Rush AJ. Ultradian rhythms and temporal coherence in sleep EEG in depressed children and adolescents, 338
Arnold LM. See Keck PE Jr
Arolt V. See Lencer R
Aronen HJ. See Laakso MP
Asenbaum S. See Neumeister A. See Willeit M
Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study, 305
Ayoub EM. See Murphy TK

Baldwin R. See Bremner JD. See Laruelle M
Ballenger JC. See George MS
Balraj E. See Bligh-Glover W
Bartko JJ. See Perkins DO
Bartlett E. See Parwani A
Basile VS. See Masellis M.
Bauer L. See Costa L
Bauer U. See Weike AI
Beersma DGM. See Koorengevel KM
Begaz T. See Hollander E
Begleiter H. See Costa L
Belger A. See Krystal JH
Beltramello A. See Laakso MP
Ben-Shakhar G. See Peri T
Bengzon J. See Madsen TM
Bennett A. See D'Souza DC. See Krystal JH
Berg P. See Klein C
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients, 351
Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression, 332
Berrettini WH. See Kaye WH
Berrettini WH. Susceptibility loci for bipolar disorder: overlap with inherited vulnerability to schizophrenia, 245
Berthoz A. See Viaud-Delmon I
Bethea CL, Mirkes SJ, Shively CA, Adams MR. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques, 562
Bianchetti A. See Laakso MP
Bjerkenstedt L. See Flyckt L
Blake J. See Engdahl BE
Bligh-Glover W, Kolli TN, Shapiro-Kulnane L, Dilley GE, Friedman L, Balraj E, Rajkowska G, Stockmeier CA. The serotonin transporter in the midbrain of suicide victims with major depression, 1015
Bolwig TG. See Madsen TM
Bonello-Cintron CM. See Vakili K
Bonsignori A. See Wong EHF
Borchelt M. See Hillen T
Borg J. See Flyckt L
Borg K. See Flyckt L
Bosmans E. See Maes M
Boutros NN. See Berman RM
Boyce AA. See Morrison MF
Braff DL. See Light GA. See Varty GB
Brambilla F. See Gerra G
Braselton J. See Sprouse J
Braun HA. See Huber MT
Bremner JD. See Rasmusson AM
Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E, Cappiello A, Woods S, Baldwin R, Charney DS. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder, 96
Breslau N. See Johnson EO
Breslau N, Chilcoat HD. Psychiatric sequelae of low birth weight at 11 years of age, 1005
Breslau N, Chilcoat HD, Johnson EO, Andreski P, Lucia VC. Neurologic soft signs and low birthweight: their association and neuropsychiatric implications, 71
Brown ES. See McElroy SL
Brücke T. See Neumeister A. See Willeit M
Brunner DP. See Cajochen C
Bulik CM. See Kaye WH
Burnet PWJ, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia, 80
Burt T. See George MS
Buxhoeveden D, Roy E, Switala A, Casanova MF. Reduced interneuronal space in schizophrenia, 681-corr

Cajochen C, Brunner DP, Kraüchi K, Graw P, Wirz-Justice A. EEG and subjective sleepiness during extended wakefulness in seasonal affective disorder: circadian and homeostatic influences, 610
Cannon TD. See Glahn DC. See Turetsky BI
Cappiello A. See Berman RM. See Bremner JD

Abbreviations:
ed, editorial
corr, correspondence

© 2000 Society of Biological Psychiatry

0006-3223/00/$20.00
PII S0006-3223(00)00924-0

Carfagna N. See Wong EHF
Carroll BJ. See Cassidy F
Carroll KM. See George TP
Cartwright C. See Hollander E
Casali S. See Akil N
Casanova MF. See Buxhoeveden D
Cassello K. See D'Souza DC
Cassidy F, Ritchie JC, Verghese K, Carroll BJ. Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors, 677
Cawthra E. See Olincy A
Chakravorty S. See Parwani A
Chappell PB. See Parwani A
Charney DS. See Berman RM. See Bremner JD. See D'Souza DC. See Krystal JH. See Morgan CA III. See Rasmusson AM
Charney DS. Our rapid publication policy, 167-ed
Charney DS. The use of placebos in randomized clinical trials of mood disorders: well justified, but improvements in design are indicated, 687-ed
Chawarski MC. See George TP. See Schottenfeld RS
Chilcoat HD. See Breslau N
Christophe A. See Maes M
Cohen-Salmon C. See Pardon M-C
Constantoine D. See Soloff PH
Cook EH Jr. See Geller B
Coplan JD, Wolk SI, Goetz RR, Ryan ND, Dahl RE, Mann JJ, Weissman MM. Nocturnal growth hormone secretion studies in adolescents with or without major depression re-examined: integration of adult clinical follow-up data, 594
Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D, Endicott J. Family history and symptom levels during treatment for bipolar I affective disorder, 1034
Costa L, Bauer L, Kuperman S, Porjesz B, O'Connor S, Hesselbrock V, Rohrbaugh J, Begleiter H. Frontal P300 decrements, alcohol dependence, and antisocial personality disorder, 1064
Costa RM. See Silva AJ
Cowen PJ. See Sharpley AL
Critchley HD, Simmons A, Daly EM, Russell A, van Amelsvoort T, Robertson DM, Glover A, Murphy DGM. Prefrontal and medial temporal correlates of repetitive violence to self and others, 928
Czekalla J. See Volz H-P

Dahl RE. See Coplan JD
Daly EM. See Critchley HD
Dannon PN. See Grunhaus L
Davidson RJ. See Kalin NH
Davidson RJ, Marshall JR, Tomarken AJ, Henriques JB. While a phobic waits: regional brain electrical and autonomic activity in social phobics during anticipation of public speaking, 85
Davis KL. See Harvey PD. See Richardson-Burns SM
DeCaria CM. See Hollander E
Deldin P. See Kimble M
Delsignore R. See Gerra G
den Boer JA. See Koorengevel KM. See Rinne T
Denicoff KD. See McElroy SL. See Post RM
Devlin B. See Kaye WH
Dilley GE. See Bligh-Glover W
Dolberg OH. See Grunhaus L
Doty L. See George DT
D'Souza DC. See Krystal JH. See Laruelle M
D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans, 450
Duncan EJ. See Parwani A
Duncan GE. See Marx CE

Eberly RE. See Engdahl BE
Edgar CL. See Akil N
Edman G. See Flyckt L
Efferen TR. See Parwani A
Elgersma Y. See Silva AJ
Emslie GJ. See Armitage R
Endicott J. See Coryell W
Engdahl BE, Eberly RE, Hurwitz TD, Mahowald MW, Blake J. Sleep in a community sample of elderly war veterans with and without posttraumatic stress disorder, 520

Falkai P, Schneider-Axmann T, Honer WG. Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality, 937
Fava M. See Vakili K
Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia, 8
Fernstrom JD. See Kaye WH
Fernstrom MH. See Kaye WH
Ferri M. See Gerra G
Fichter MM. See Kaye WH
Finkell JN. See Hollander E
Fitzgerald KD, Moore GJ, Paulson LA, Stewart CM, Rosenberg DR. Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder, 174
Fletcher PJ. See Wadenberg M-LG
Flyckt L, Borg J, Borg K, Ansved T, Edman G, Bjerkenstedt L, Wiesel F-A. Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia, 991
Ford JM. See Mathalon DH
Fox P. See Morgan CA III
Franklin S. See Wong EHF
Freedman R. See Olincy A. See Waldo MC
Friedman JI. See Harvey PD
Friedman L. See Bligh-Glover W
Frisoni GB. See Laakso MP
Frye MA. See McElroy SL
Fujita M. See Bremner JD
Fulton MK, Armitage R, Rush AJ. Sleep electroencephalographic coherence abnormalities in individuals at high risk for depression: a pilot study, 618

Gandevia SC. See Loo CK
Geller B, Cook EH Jr. Ultradian rapid cycling in prepubertal and early adolescent bipolarity is not in transmission disequilibrium with val/met COMT alleles, 605
Gendall KA. See Kaye WH
George DT, Hibbeln JR, Ragan PW, Umhau JC, Phillips MJ, Doty L, Hommer D, Rawlings RR. Lactate-induced rage and panic in a select group of subjects who perpetrate acts of domestic violence, 804
George MS. See Rush AJ
George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC. Vagus nerve

stimulation: a new tool for brain research and therapy, 287
George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial, 1080
Gérardin P. See Pardon M-C
German DC. See Young KA
Geroldi C. See Laakso MP
Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F. Long-lasting effects of (±)3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans, 127
Gershon ES. Bipolar illness and schizophrenia as oligogenic diseases: implications for the future, 240
Gershon S. See Levine J
Geyer MA. See Varty GB
Gil R. See D'Souza DC. See Laruelle M
Giller C. See Rush AJ
Gilmore JH. See Marx CE
Glahn DC, Cannon TD, Gur RE, Ragland JD, Gur RC. Working memory constrains abstraction in schizophrenia, 34
Glover A. See Critchley HD
Gluck JP. See Lewis MH
Goddard AW. See Bremner JD
Goetz RR. See Coplan JD
Goldman D. See Heinz A. See Kaye WH
Goldman J. See George MS
Gonzenbach S. See Parwani A
Goodman R. See Rush AJ
Goodman WK. See Murphy TK
Goodnick PJ, Kumar AM. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression, 846-corr
Gordijn MCM. See Koorengevel KM
Granda BW. See Zalma A
Graw P. See Cajochen C
Greenblatt DJ. See Zalma A
Greenfield G. See Morgan CA III
Greer PJ. See Soloff PH
Griez E. See van Beek N
Grunhaus L, Dannon PN, Schreiber S, Dolberg OH, Amiaz R, Ziv R, Lefkifker E. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study, 314
Guo LS. See Kellner M
Gur RC. See Glahn DC
Gur RE. See Glahn DC. See Turetsky BI

Haines S. See Rush AJ
Halmi KA. See Kaye WH
Hamm AO. See Weike AI
Harmatz JS. See Zalma A
Haroutunian V. See Richardson-Burns SM
Harris JG. See Olincy A. See Waldo MC
Harvey PD, Moriarty PJ, Friedman JI, White L, Parrella M, Mohs RC, Davis KL. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas, 962
Hauger RL. See Morgan CA III. See Rasmusson AM
Hazlett G. See Morgan CA III
Heinks T. See Klein C
Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity, 643
Hellhammer DH. See Wolf OT
Heninger GR. See Berman RM. See Rosenbaum JF
Henriques JB. See Davidson RJ
Hensley LL. See Lewis MH
Hesselbrock V. See Costa L
Hibbeln JR. See Fenton WS. See George DT
Hicks PB. See Young KA
Hilger E. See Willeit M
Hill SY, Shen S, Locke J, Lowers L, Steinhauer S, Konicky C. Developmental changes in postural sway in children at high and low risk for developing alcohol-related disorders, 501
Hillen T, Lun A, Reischies FM, Borchelt M, Steinhagen-Thiessen E, Schaub RT. DHEA-S plasma levels and incidence of Alzheimer's disease, 161
Hoff P. See Meincke U
Hoffman RE. See Berman RM
Hoffmann RF. See Armitage R
Hoffmann WP. See Wong EHF
Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling, 813
Holsboer F. See Auer DP. See Kellner M
Holstein W. See Volz H-P
Hommer D. See George DT. See Heinz A
Honer WG. See Falkai P
Horwitz RI. See Mattocks KM
Hu XS. See Berman RM
Huber MT, Braun HA, Krieg JC. Effects of noise on different disease states of recurrent affective disorders, 634
Hurwitz TD. See Engdahl BE
Husain MM. See George MS. See Rush AJ
Hyman SE. The NIMH perspective: next steps in schizophrenia research, 1
Hyman SE, Shore D. An NIMH perspective on the use of placebos 689-ed
Hyslop DK. See Wong EHF

Innis RB. See Bremner JD. See Laruelle M
Israël I. See Viaud-Delmon I

Jean-Louis G, Kripke DF, Ancoli-Israel S, Klauber MR, Sepulveda RS. Sleep duration, illumination, and activity patterns in a population sample: effects of gender and ethnicity, 921
Jensen PN. See Schmidt K
Johnson EO. See Breslau N
Johnson EO, Breslau N. Increased risk of learning disabilities in low birth weight boys at age 11 years, 490
Jones DW. See Heinz A
Joubert C. See Pardon M-C
Jouvent R. See Viaud-Delmon I

Kalin NH, Shelton SE, Davidson RJ. Cerebrospinal fluid corticotropin-releasing hormone levels are elevated in monkeys with patterns of brain activity associated with fearful temperament, 579
Kallman MJ. See Vandergriff J
Kaloupek D. See Kimble M
Kaplan A. See Kaye WH
Kapur S. See Wadenberg M-LG
Karper LP. See D'Souza DC. See Krystal JH
Kasper S. See Neumeister A. See Willeit M

Katz IR. See Morrison MF
Kaufman M. See Kimble M
Kaye WH, Gendall KA, Fernstrom MH, Fernstrom JD, McConaha CW, Weltzin TE. Effects of acute tryptophan depletion on mood in bulimia nervosa, 151
Kaye WH, Lilenfeld LR, Berrettini WH, Strober M, Devlin B, Klump KL, Goldman D, Bulik CM, Halmi KA, Fichter MM, Kaplan A, Woodside DB, Treasure J, Plotnicov KH, Pollice C, Rao R, McConaha CW. A search for susceptibility loci for anorexia nervosa: methods and sample description, 794
Keck PE Jr. See McElroy SL
Keck PE Jr, Welge JA, McElroy SL, Arnold LM, Strakowski SM. Placebo effect in randomized, controlled studies of acute bipolar mania and depression, 748
Keck PE Jr, Welge JA, Strakowski SM, Arnold LM, McElroy SL. Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorder, 756
Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F, Yehuda R. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder, 107
Kelly TM. See Soloff PH
Kennedy JL. See Masellis M.
Ketter TA. See Winsberg ME
Kiefer M. See Weisbrod M
Kimble M, Kaloupek D, Kaufman M, Deldin P. Stimulus novelty differentially affects attentional allocation in PTSD, 880
Kimble M, Lyons M, O'Donnell B, Nestor P, Niznikiewicz M, Toomey R. The effect of family status and schizotypy on electrophysiologic measures of attention and semantic processing, 402
Kirsch I. Are drug and placebo effects in depression additive?, 733
Kirschbaum C. See Wolf OT
Klauber MR. See Jean-Louis G
Klein C, Heinks T, Andresen B, Berg P, Moritz S. Impaired modulation of the saccadic contingent negative variation preceding antisaccades in schizophrenia, 978
Klump KL. See Kaye WH
Knable M. See Fenton WS
Knight DL. See Owens MJ
Ko GN. See Parwani A
Kolli TN. See Bligh-Glover W
Konicky C. See Hill SY
Könönen M. See Laakso MP
Koorengevel KM, Beersma DGM, Gordijn MCM, den Boer JA, van den Hoofdakker RH, Body temperature and mood variations during forced desynchronization in winter depression: a preliminary report, 355
Kosten TR. See George TP. See Schottenfeld RS
Kowatch RA. See Armitage R
Kraemer HC. See Schatzberg AF
Kraft E. See Auer DP
Kraüchi K. See Cajochen C
Krieg JC. See Huber MT
Kripke DF. See Jean-Louis G
Krishman KRR. Efficient trial designs to reduce placebo requirements, 724
Krystal JH. See Berman RM. See D'Souza DC. See Laruelle M
Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, Lipschitz D, Abi-Dargham A, Charney DS. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions, 137
Kudielka BM. See Wolf OT
Kumar AM. See Goodnick PJ
Kuperman S. See Costa L
Kupka EW. See McElroy SL

Laakso MP, Frisoni GB, Könönen M, Mikkonen M, Beltramello A, Geroldi C, Bianchetti A, Trabucchi M, Soininen H, Aronen HJ. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study, 1056
Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ Sr, Soininen H. Hippocampus in Alzheimer's disease, 557
Lafer B. See Vakili K
Laruelle M, Abi-Dargham A, van Dyck C, Gil R., D'Souza C, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [^{123}I]β-CIT, 371
Lasko NB. See Rauch SL
Lavori PW. Placebo control groups in randomized treatment trials: a statistician's perspective, 717
Leber P. The use of placebo control groups in the assessment of psychiatric drugs: an historical context, 699
Lederhendler I. See Vitiello B
Lefkifker E. See Grunhaus L
Lehtovirta M. See Laakso MP
Lencer R, Malchow CP, Trillenberg-Krecker K, Schwinger E, Arolt V. Eye-tracking dysfunction (ETD) in families with sporadic and familial schizophrenia, 391
Leon AC. See Coryell W
Leonard S. See Waldo MC
Levengood R. See Kellner M
Leverich GS. See McElroy SL. See Post RM
Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients, 586
Lewis DA. See Akil N
Lewis L. The National Depressive and Manic-Depressive Association: an introduction, 692-ed
Lewis MH, Gluck JP, Petitto JM, Hensley LL, Ozer H. Early social deprivation in nonhuman primates: long-term effects on survival and cell-mediated immunity, 119
Liang C-L. See Young KA
Lieberman JA. See Marx CE
Light GA, Braff DL. Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients?, 463
Lilenfeld LR. See Kaye WH
Lim KO. See Mathalon DH
Lin A. See Maes M
Lindvall O. See Madsen TM
Linnoila M. See Heinz A
Lipinski B. See Auer DP
Lipschitz D. See Krystal JH
Lisanby S. See George MS
Locke J. See Hill SY
Loo CK, Taylor JL, Gandevia SC, McDarmont BN, Mitchell PB, Sachdev PS. Transcranial magnetic stimulation (TMS) in controlled

treatment studies: are some "sham" forms active?, 325
Lowers L. See Hill SY
Lucia VC. See Breslau N
Lun A. See Hillen T
Luthringer R. See Toussaint M
Lyons M. See Kimble M

Macciardi FM. See Masellis M.
Macher J-P. See Toussaint M
Macklin ML. See Rauch SL
Madonick SH. See Parwani A
Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall O, Tingström A. Increased neurogenesis in a model of electroconvulsive therapy, 1043
Maes M, Christophe A, Bosmans E, Lin A, Neels H. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress, 910
Mahowald MW. See Engdahl BE
Malchow CP. See Lencer R
Manaye KF. See Young KA
Mann JJ. See Coplan JD
Marangell LB. See George MS. See Rush AJ
Marshall JR. See Davidson RJ
Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex, 1000
Marzinzik F. See Weisbrod M
Marzocchi GF. See Gerra G
Masellis M, Basile VS, Özdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine, 252
Mason J. See Morgan CA III
Mathalon DH, Ford JM, Rosenbloom M, Pfefferbaum A. P300 reduction and prolongation with illness duration in schizophrenia, 413
Mattocks KM, Horwitz RI. Placebos, acute control groups, and the unpredictability paradox, 693
Maurer I. See Volz H-P
Mazzanti C. See Heinz A
McAndrews MA. See Olincy A
McArthur RA. See Wong EHF
McClure RJ. See Levine J
McConaha CW. See Kaye WH
McDarmont BN. See Loo CK
McElroy SL. See Keck PE Jr
McElroy SL, Suppes T, Keck PE Jr, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar disorders, 1025
McInerney SC. See Rauch SL
McRae KA. See Olincy A
Meador-Woodruff JH. See Richardson-Burns SM
Meincke U, Töpper R, Hoff P. Influence of stimulus control on the excitability of the electrically elicited blink reflex in patients with schizophrenia, 43
Meltzer CC. See Soloff PH
Meltzer HY. See Masellis M.
Meltzer HY. Genetics and etiology of schizophrenia and bipolar disorder, 171-ed
Miano AP. See Berman RM
Mikkonen M. See Laakso MP
Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective, 707
Mirkes SJ. See Bethea CL
Mitchell PB. See Loo CK
Mohs EC. See Harvey PD
Moore GJ. See Fitzgerald KD
Morgan CA III. See Rasmusson AM
Morgan CA III, Wang S, Mason J, Southwick SM, Fox P, Hazlett G, Hauger RL, Charney DS, Greenfield G. Hormone profiles in humans experiencing military survival training, 891
Morgan CA III, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS. Plasma neuropeptide-Y concentrations in humans exposed to military survival training, 902
Moriarty PJ. See Harvey PD
Moritz S. See Klein C
Morrison MF, Redei E, TenHave T, Parmelee P, Boyce AA, Sinha PS, Katz IR. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population, 144
Morrissey K. See D'Souza DC
Morrow AL. See Marx CE
Müller N. See Schwarz MJ
Murphy DGM. See Critchley HD
Murphy TK, Goodman WK, Ayoub EM, Voeller KK. On defining Sydenham's chorea: where do we draw the line?, 851
Muzet A. See Toussaint M

Nahas Z. See George MS. See Rush AJ
Narasimhan M. See Berman RM
Neels H. See Maes M
Nemeroff CB. See Owens MJ
Neri E. See Gerra G
Nestor P. See Kimble M
Neumeister A. See Willeit M
Neumeister A, Pirker W, Willeit M, Praschak-Rieder N, Asenbaum S, Brücke T, Kasper S. Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [^{123}I]-2β-carbomethoxy-3β(4-iodophenyl)tropane and single photon emission computed tomography, 158
Niznikiewicz M. See Kimble M
Nolen WA. See McElroy SL

O'Connor P. See Schottenfeld RS
O'Connor S. See Costa L
O'Donnell B. See Kimble M
Olesen OV. See Schmidt K
Olincy A. See Waldo MC
Olincy A, Ross RG, Harris JG, Young DA, McAndrews MA, Cawthra E, McRae KA, Sullivan B, Adler LE, Freedman R. The P50 auditory event–evoked potential in adult attention-deficit disorder: comparison with schizophrenia, 969
Oliveto A. See Schottenfeld RS
Oren DA. See Berman RM
Orr SP. See Peri T. See Rauch SL
Owens MJ, Knight DL, Nemeroff CB. Paroxetine binding to the rat norepinephrine transporter in vivo, 842
Özdemir V. See Masellis M.
Ozer H. See Lewis MH

Pakes J. See George TP. See Schottenfeld RS
Panchalingam K. See Levine J
Pardon M-C, Gérardin P, Joubert C, Pérez-Diaz F, Cohen-Salmon C. Influence of prepartum chronic ultramild stress on maternal pup care behavior in mice, 858
Parmelee P. See Morrison MF
Parrella M. See Harvey PD

Partanen K. See Laakso MP
Parwani A, Duncan EJ, Bartlett E, Madonick SH, Efferen TR, Rajan R, Sanfilipo M, Chappell PB, Chakravorty S, Gonzenbach S, Ko GN, Rotrosen JP. Impaired prepulse inhibition of acoustic startle in schizophrenia, 662
Paulson LA. See Fitzgerald KD
Paulus MP. See Varty GB
Pérez-Diaz F. See Pardon M-C
Peri T, Ben-Shakhar G, Orr SP, Shalev AY. Psychophysiologic assessment of aversive conditioning in posttraumatic stress disorder, 512
Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials, 762
Petitto JM. See Lewis MH
Pettegrew JW. See Levine J
Pfefferbaum A. See Mathalon DH
Phillips MJ. See George DT
Piercey MFP. See Wong EHF
Pierri JN. See Akil N
Pillay SS. See Vakili K
Pirker W. See Neumeister A. See Willeit M
Pitman RK. See Rauch SL
Plotnicov KH. See Kaye WH
Pollice C. See Kaye WH
Porjesz B. See Costa L
Porsolt RD. See Wong EHF
Post RM. See McElroy SL
Post RM, Denicoff KD, Leverich GS. Special issues in trial design and use of placebo in bipolar illness, 727
Praschak-Rieder N. See Neumeister A. See Willeit M
Preut R. See Wolf OT
Pulver AE. Search for schizophrenia susceptibility genes, 221
Pütz B. See Auer DP

Ragan PW. See George DT. See Heinz A
Ragland JD. See Glahn DC
Rajan R. See Parwani A
Rajdev S. See Tomitaka M
Rajkowska G. See Bligh-Glover W
Rao R. See Kaye WH
Rapoport A. See Levine J
Rasmussen K. See Vandergriff J
Rasmusson AM. See Morgan CA III
Rasmusson AM, Hauger RL, Morgan CA III, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD, 526
Rauch SL. Neuroimaging research and the neurobiology of obsessive–compulsive disorder: where do we go from here?, 168-ed
Rauch SL, Whalen PJ, Shin LM, McInerney SC, Macklin ML, Lasko NB, Orr SP, Pitman RK. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study, 769
Rawlings RR, See George DT
Redei E. See Morrison MF
Reischies FM. See Hillen T
Renshaw PF. See Vakili K
Reynolds L. See Sprouse J
Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus, 22
Riedel M. See Schwarz MJ
Riehemann S. See Volz H-P
Riekkinen PJ Sr. See Laakso MP
Rinne T, Westenberg HGM, den Boer JA, van den Brink W. Serotonergic blunting to meta-chlorophenyl-piperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients, 548
Rintelmann J. See Armitage R
Ritchie JC. See Cassidy F
Robertson DM. See Critchley HD
Rochussen J. See McElroy SL
Rohrbaugh J. See Costa L
Rosenbaum JF, Heninger G. Vagus nerve stimulation for treatment-resistant depression, 273-ed
Rosenberg DR. See Fitzgerald KD
Rosenbloom M. See Mathalon DH
Ross RG. See Olincy A. See Waldo MC
Rotrosen JP. See Parwani A
Roy E. See Buxhoeveden D
Rush AJ. See Armitage R. See Fulton MK. See George MS
Rush AJ. The use of placebos in unipolar major depression: the current status, 745
Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RK Jr, Goodman R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study, 276
Russell A. See Critchley HD
Ryan ND. See Coplan JD
Rzanny R. See Volz H-P

Sachdev PS. See Loo CK
Sachs N. See Winsberg ME
Sackeim HA. See George MS. See Rush AJ
Sanacora G. See Berman RM
Sanfilipo M. See Parwani A
Sastny J. See Willeit M
Sauer H. See Volz H-P
Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression, 736
Schaub RT. See Hillen T
Schill J. See Auer DP
Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant, 164
Schneider-Axmann T. See Falkai P
Schottenfeld RS. See George TP
Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR. Thrice-weekly versus daily buprenorphine maintenance, 1072
Schreiber S. See Grunhaus L
Schürmeyer TH. See Wolf OT
Schwarz MJ, Riedel M, Ackenheil M, Müller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated schizophrenic patients, 29
Schwinger R. See Lencer R
Seibyl J. See Laruelle M
Sepulveda RS. See Jean-Louis G
Shader RI. See Zalma A
Shalev AY. See Peri T
Shapiro-Kulnane L. See Bligh-Glover W
Sharp FR. See Tomitaka M
Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT_{2C} receptors in vivo, 468
Shelton SE. See Kalin NH
Shen S. See Hill SY
Shin LM. See Rauch SL
Shively CA. See Bethea CL
Shore D. See Hyman SE

Siegler I. See Viaud-Delmon I
Silbersweig D. See Bremner JD
Sills TL. See Wadenberg M-LG
Silva AJ, Elgersma Y, Costa RM. Molecular and cellular mechanisms of cognitive function: implications for psychiatric disorders, 200
Simmons A. See Critchley HD
Simpson RK Jr. See Rush AJ
Sinha PS. See Morrison MF
Smesny S. See Volz H-P
Soininen H. See Laakso MP
Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM. A fenfluramine-activated FDG-PET study of borderline personality disorder, 540
Solomon D. See Coryell W
Sommer M. See Volz H-P
Sonders MS. See Wong EHF
Southwick SM. See Morgan CA III. See Rasmusson AM
Spielman D. See Winsberg ME
Spitzer M. See Weisbrod M
Sprouse J, Braselton J, Reynolds L. 5-HT_{1A} agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus, 1050
St George-Hyslop PH. Molecular genetics of Alzheimer's disease, 182
Staib L. See Bremner JD
Staner L. See Toussaint M
Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders, 296
Steinhagen-Thiessen E. See Hillen T
Steinhauer S. See Hill SY
Stern E. See Bremner JD
Stewart CM. See Fitzgerald KD
Stockmeier CA. See Bligh-Glover W
Strakowski SM. See Keck PE
Strober M. See Kaye WH
Sturwold R. See D'Souza DC
Sullivan B. See Olincy A
Sullivan EV. See Mathalon DH
Suppes T. See McElroy SL
Swift M, Swift RG. Psychiatric disorders and mutations at the Wolfram syndrome locus, 787
Swift RG. See Swift M
Switala A. See Buxhoeveden D

Tate DL. See Winsberg ME
Tauscher J. See Willeit M
Taylor JL. See Loo CK
TenHave T. See Morrison MF
Timpano M. See Gerra G
Tingström A. See Madsen TM
Tinholt PM. See Wong EHF
Tomarken AJ. See Davidson RJ
Tomitaka M, Tomitaka S, Rajdev S, Sharp FR. Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats, 836
Tomitaka S. See Tomitaka M
Toomey R. See Kimble M
Töpper R. See Meincke U
Toussaint M, Luthringer R, Staner L, Muzet A, Macher J-P. Changes in EEG power density during sleep laboratory adaptation in depressed inpatients, 626
Trabucchi M. See Laakso MP
Treasure J. See Kaye WH
Treschow A. See Madsen TM
Trillenberg-Krecker K. See Lencer R
Tsuang M. Schizophrenia: genes and environment, 210
Turetsky BI, Cannon TD, Gur RE. P300 subcomponent abnormalities in schizophrenia: III. Deficits in unaffected siblings of schizophrenic probands, 380
Turvey C. See Coryell W

Umhau JC. See George DT

Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study, 1087
van Amelsvoort T. See Critchley HD
van Beek N, Griez E. Reactivity to a 35% CO_2 challenge in healthy first-degree relatives of patients with panic disorder, 830
van den Brink W. See Rinne T
van den Hoofdakker RH. See Koorengevel KM
van Dyck C. See Laruelle M
Vandergriff J, Kallman MJ, Rasmussen K. Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats, 874
Varty GB, Paulus MP, Braff DL, Geyer MA. Environmental enrichment and isolation rearing in the rat: effects on locomotor behavior and startle response plasticity, 864
Vassallo CM. See Sharpley AL
Verghese K. See Cassidy F
Viaud-Delmon I, Siegler I, Israël I, Jouvent R, Berthoz A. Eye deviation during rotation in darkness in trait anxiety: an early expression of perceptual avoidance?, 112
Vitiello B, Lederhendler I. Research on eating disorders: current status and future prospects, 777
Vitouch O. See Willeit M
Voeller KK. See Murphy TK
Volz H-P, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, Holstein W, Czekalla J, Sauer H. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a ^{31}P chemical shift spectroscopic-imaging study, 954
von Moltke LL. See Zalma A

Wadenberg M-LG, Sills TL, Fletcher PJ, Kapur S. Antipsychoticlike effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats, 670
Waldo MC, Adler LE, Leonard S, Olincy A, Ross RG, Harris JG, Freedman R. Familial transmission of risk factors in the first-degree relatives of schizophrenic people, 231
Wang S. See Morgan CA III
Watson SJ. See Richardson-Burns SM
Weike AI, Bauer U, Hamm AO. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients, 61
Weinberg WA. See Armitage R
Weinberger DR. See Heinz A
Weisbrod M, Kiefer M, Marzinzik F, Spitzer M. Executive control is disturbed in schizophrenia: evidence from event-related potentials in a Go/NoGo task, 51
Weissman MM. See Coplan JD
Welge JA. See Keck PE
Weltzin TE. See Kaye WH
Westenberg HGM. See Rinne T
Whalen PJ. See Rauch SL
White J. See D'Souza DC
White L. See Harvey PD
White T. See Bremner JD
Wiedemann K. See Kellner M
Wiesel F-A. See Flyckt L

Willeit M. See Neumeister A
Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O, Tauscher J, Hilger E, Stastny J, Brücke T, Kasper S. [^{123}I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder, 482
Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. Decreased dorsolateral prefrontal *N*-acetyl-aspartate in bipolar disorder, 475
Wirz-Justice A. See Cajochen C
Wolf OT, Preut R, Hellhammer DH, Kudielka BM, Schürmeyer TH, Kirschbaum C. Testosterone and cognition in elderly men: a single testosterone injection blocks the practice effect in verbal fluency, but has no effect on spatial or verbal memory, 650
Wolk SI. See Coplan JD
Wong CM. See Hollander E
Wong EHF, Sonders MS, Amara SG, Tinholt PM, Piercey MFP, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor, 818
Woods S. See Bremner JD
Woodside DFB. See Kaye WH
Wyatt RJ. See Perkins DO

Yassouridis A. See Kellner M
Yehuda R. See Kellner M
Young DA. See Olincy A
Young KA, Manaye KF, Liang C.-L, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia, 944
Yurgelun-Todd DA. See Vakili K

Zaimovic A. See Gerra G
Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors, 655
Zambelli U. See Gerra G
Ziv R. See Grunhaus L
Zuzarte E. See D'Souza DC

Subject Index to Volume 47

Abstraction
  in schizophrenia, working memory affecting, 34
N-Acetyl-aspartate
  dorsolateral prefrontal levels in bipolar disorder, 475
  thalamic, in pediatric obsessive–compulsive disorder, 174
Adhesion molecules
  ICAM-1 levels in schizophrenia, 29
Adolescence
  nocturnal growth hormone secretion, 594
  sleep EEG coherence in depression, 338
  ultradian rapid cycling in bipolar disorders, 605
Affective disorders
  and effects of noise intensity, 634
  neurokinin-1 receptors in, 80
Age
  and brain function studies, 1064
Aged subjects
  cognitive function
    related to DHEA-S levels, 144
    in schizophrenic patients, 962
  sleep and posttraumatic stress disorder in elderly veterans, 520
  testosterone and cognition in elderly men, 650
Aggression
  and behavior after prepartum ultramild stress in mice, 858
  and brain regions in violent behavior, 928
  and fenfluramine challenge in borderline personality disorder, 540
  and lactate-induced rage and panic, 804
Alcohol withdrawal
  and moxonidine affecting acoustic startle response in rats, 874
Alcoholism
  and frontolimbic brain pathology, 1064
  risk with postural sway in childhood, 501
  serotonin transport genotypes in, 643
Allopregnanolone
  in cerebral cortex, olanzapine affecting, 1000
Alzheimer disease
  DHEA-S levels in, 161
  entorhinal cortex in, 1056
  hippocampus in, 557, 1056
  molecular genetics of, 183
Amino acids
  cerebrospinal fluid levels affected by glycine and D-cycloserine, 450
Amoxapine
  antipsychoticlike activity of, 670
cAMP response element binding protein (CREB)
  and mechanisms in cognitive function, 200
Amygdala
  responses in posttraumatic stress disorder, 769
  role in violent behavior, 928
β Amyloid precursor protein
  in Alzheimer disease, 183
Animal studies
  brain corticotropin-releasing hormone activity in monkeys, 579
  environmental stimuli affecting development in rats, 864
  fluoxetine preventing neurotoxicity of NMDA receptor antagonists in rats, 836
  moxonidine affecting acoustic startle response in ethanol withdrawal in rats, 874
  neurogenesis after electroconvulsive seizures in rats, 1043
  olanzapine affecting allopregnanolone in rat cerebral cortex, 1000
  paroxetine binding to norepinephrine transporter in rats, 842
  pindolol combined with fluoxetine in rats, 1050
  prepartum ultramild stress in mice, 858
  reboxetine as norepinephrine reuptake inhibitor in rats, 818
  social deprivation affecting survival and immunity in monkeys, 119
  tryptophan hydroxylase regulation in dorsal raphe of macaques, 562
Anorexia nervosa
  genetic factors in, 794
  research on, 775
Antidepressants
  additive drug and placebo effects, 733
  citalopram in breast milk affecting infants, 164
  ketamine, 351
  reboxetine as norepinephrine reuptake inhibitor, 818
Antipsychotic drugs
  amoxapine activity in startle reflex, 670
  olanzapine
    affecting slow-wave sleep, 468
    and allopregnanolone in cerebral cortex, 1000
  pharmacogenetics of, 252
  and prepulse inhibition in schizophrenia, 61
Antisocial personality disorder
  and alcohol dependence, 1064
Anxiety
  and neuropeptide Y levels in posttraumatic stress disorder, 526
  in social phobia, 85
  spatial perception in, 112
Apolipoprotein E
  in Alzheimer disease, 183

Abbreviations:
ed, editorial
corr, correspondence

© 2000 Society of Biological Psychiatry

0006-3223/00/$20.00
PII S0006-3223(00)00925-2

Attention-deficit disorder
and P50 auditory event-related potential in adults, 969
Attentional dysfunction
and blink reflex in schizophrenia, 43
and psychiatric sequelae of low birthweight at 11 years of age, 1005
in relatives of schizophrenic people, 402
Auditory event-related potentials
and executive control in schizophrenia, 51
novel stimuli affecting, in posttraumatic stress disorder, 880
P50 amplitude
in adult attention-deficit disorder, 969
suppression deficits in schizophrenia, 463
P300 reduction
schizophrenia illness duration related to, 413
as trait of schizophrenia, 434
and schizophrenic risk factors, 402
in siblings of schizophrenic probands, 380
Autoimmunity
pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS), 851
Autonomic function
in social phobia, 85
Autoradiography
neurokinin-1 receptor binding sites in cingulate cortex, 80
Aversive conditioning
in posttraumatic stress disorder, 512

Behavior
early environmental stimuli affecting development in rats, 864
Benzodiazepines
receptor binding in panic disorder, 96
Biological Psychiatry
rapid publication policy, 167-ed
Biopsy of muscle
in schizophrenia, 991
Bipolar disorder
dorsolateral prefrontal *N*-acetyl-aspartate in, 475
family history and lithium response in, 1034
genetic factors in etiology, 171-ed
neurokinin-1 receptors in, 80
as oligogenic disease, 240
overlapping linkage with schizophrenia, 245
placebo use in, 727
in acute mania, 748
in maintenance treatment, 756
topiramate in, 1025
and ultradian rapid cycling in children and adolescents, 605
Birthweight, low
and learning disabilities in boys, 490
neurologic soft signs with, 71
psychiatric sequelae at 11 years of age, 1005
Blink reflex
in schizophrenia, 43
and neuroleptics affecting prepulse inhibition, 61
Blood–brain barrier
impairment in schizophrenia, 29
Blood pressure
measurements in social phobia, 85
and neuropeptide Y levels in posttraumatic stress disorder, 526
Borderline personality disorder
PET study with fenfluramine challenge, 540
serotonergic blunting in traumatized patients, 548
Brain
N-acetyl-aspartate levels
dorsolateral prefrontal, in bipolar disorder, 475
thalamic, in pediatric obsessive–compulsive disorder, 174
amygdala responses in posttraumatic stress disorder, 769
amygdalo-hippocampal complex in violent behavior, 928
blood–brain barrier impairment in schizophrenia, 29
corticotropin-releasing hormone activity in monkeys, 579
function after vagus nerve stimulation, 287
glutamate
cingulate cortex levels in depression, 306
receptors in schizophrenic thalamus, 22
hippocampal conditions. *See* Hippocampus
neurokinin-1 receptors in mood disorders or schizophrenia, 80
olanzapine affecting allopregnanolone in cerebral cortex, 1000
regional electrical activity in social phobia, 85
seasonal variation of serotonin transporter binding sites, 158
tryptophan hydroxylase regulation in dorsal raphe of macaques, 562
Breast milk
citalopram in, affecting infants, 164
Bromodeoxyuridine
in rat dentate gyrus cells after electroconvulsive seizures, 1043
Bulimia nervosa
research on, 775
tryptophan depletion in, 151
Buprenorphine
maintenance treatment in heroin dependence, 1072
with disulfiram for cocaine dependence, 1080

CaM kinase II
and mechanisms in cognitive function, 200
Carbon dioxide challenge test
in relatives of panic disorder patients, 830
Catechol-*O*-methyltransferase
alleles in prepubertal bipolarity, 605
Cerebrospinal fluid
amino acid levels affected by glycine and D-cycloserine, 450
corticotropin-releasing hormone levels and brain activity in monkeys, 579
glutamine levels in depression, 586
Chaos
and effects of noise on affective disorders, 634
Child abuse
and serotonergic blunting in borderline personality disorder, 548

Children
learning disabilities in low birthweight boys, 490
neurologic soft signs associated with low birthweight, 71
pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS), 851
postural sway and alcoholism risk, 501
psychiatric sequelae of low birthweight at 11 years of age, 1005
sleep EEG coherence in depression, 338
spectroscopic imaging in obsessive–compulsive disorder, 174
ultradian rapid cycling in bipolar disorders, 605
m-Chlorophenylpiperazine
formation from trazodone affected by drugs, 655
prolactin responses in traumatized borderline personality patients, 548
Cholecystokinin tetrapeptide
effects in posttraumatic stress disorder, 107
Chromosomes
markers linked to schizophrenia, 221
Cingulate cortex
glutamate levels in depression, 305
neurokinin-1 receptors in mood disorders or schizophrenia, 80
Circadian rhythms
in seasonal affective disorder
and forced desynchronization, 355
and sleepiness, 610
and sleep duration, 921
β-CIT SPECT imaging studies
dopamine and serotonin transporters in schizophrenia, 371
in seasonal affective disorder, 482
seasonal variations in binding sites, 158
serotonin transporter genotypes in alcoholism, 643
Citalopram
in breast milk, affecting infants, 164
Clinical trials
active control groups in, 693
disulfiram for cocaine dependence in buprenorphine-maintained subjects, 1080
placebos in, 687-ed. *See also* Placebos in clinical trials
sample size requirements in, 762
Clonidine
and acoustic startle response in ethanol withdrawal in rats, 874
Clozapine
pharmacogenetic studies, 252
Cocaine dependence
and disulfiram in buprenorphine-maintained subjects, 1080
Cognitive function
and abstraction and memory in schizophrenia, 34
and DHEA-S levels in aged subjects, 144
in geriatric schizophrenic patients, 962
ketamine affecting, 137
molecular and cellular mechanisms of, 200
and testosterone levels in elderly men, 650
Compulsive behavior
and fluvoxamine in pathologic gambling, 813
obsessive. *See* Obsessive–compulsive disorders
Corticotropin-releasing hormone
in cerebrospinal fluid, and brain activity in monkeys, 579
Cortisol
and dexamethasone metabolism, 677
response to cholecystokinin tetrapeptide, 107
serum levels
in depressed aged subjects, 144
increased after survival training, 891, 902
in MDMA users, 127
Cycling in bipolar disorder
topiramate affecting, 1025
ultradian rapid cycling in children and adolescents, 605
D-Cycloserine
and amino acid levels in cerebrospinal fluid, 450
Cytochromes
trazodone metabolism by CYP3A, 655
Cytokines
proinflammatory response affected by polyunsaturated fatty acids in stress, 910

Dehydroepiandrosterone sulfate levels
in aged subjects, 144
and Alzheimer disease incidence, 161
Dementia
and DHEA-S levels in aged subjects, 144
frontotemporal, hippocampus and entorhinal cortex in, 1056
Dentate gyrus
neurogenesis after electroconvulsive seizures in rats, 1043
Depression. *See also* Bipolar disorder
additive drug and placebo effects in, 733
and circadian variations in forced desynchronization, 355
and DHEA-S levels in aged subjects, 144
and glutamine levels in cerebrospinal fluid, 586
ketamine effects in, 351
magnetic resonance spectroscopy in, 305
and mechanisms in cognitive function, 200
and mutations at Wolfram syndrome locus, 787
and neurogenesis in rat dentate gyrus after electroconvulsive seizures, 1043
neurokinin-1 receptors in, 80
postpartum, and citalopram in breast milk affecting infants, 164
and reboxetine as norepinephrine reuptake inhibitor, 818
serotonin transporter availability in seasonal affective disorder, 482
vagus nerve stimulation in, 273-ed
historical review of, 287
multicenter study of, 276
Depressive disorder, major
first-night data for sleep of inpatients, 626
hippocampal volume in, 1087
midbrain serotonin transporter in suicide victims, 1015
and nocturnal growth hormone secretion in adolescence, 594

paroxetine in, and platelet serotonin content affecting responses, 846-corr
placebos in, 736
current status of, 745
and sleep EEG coherence abnormalities, 618
transcranial magnetic stimulation in, 314
randomized clinical trial of, 332
Desynchonization, forced
and circadian temperature and mood variations, 355
Development
and early environmental stimuli affecting behavior in rats, 864
Dexamethasone
metabolism in dexamethasone suppression tests, 677
Dissociation
response to cholecystokinin tetrapeptide, 107
Disulfiram
for cocaine dependence in buprenorphine-maintained subjects, 1080
Dizocilpine (MK801)
neurotoxicity prevented by fluoxetine, 836
Domestic violence
and lactate-induced rage and panic, 804
Dopamine
in entorhinal cortex in schizophrenia, 361
transporters in schizophrenia, 371
Dopaminergic neurotransmission
in families of schizophrenic people, 231
in obsessive-compulsive disorders, 296
Dorsal raphe
pindolol affecting firing of serotonergic neurons, 1050
serotonin transporters in depressed suicide victims, 1015
tryptophan hydroxylase regulation in monkeys, 562
Dynamic states
and effects of noise on affective disorders, 634

Early experience
environmental stimuli affecting development in rats, 864
social deprivation affecting survival and immunity in monkeys, 119
Eating disorders
research on, 775
susceptibility loci for anorexia nervosa, 794
tryptophan depletion in bulimia nervosa, 151
Electroconvulsive therapy
compared to transcranial magnetic stimulation in major depressive disorder, 314
and neurogenesis in rat dentate gyrus, 1043
Electroencephalography
EEG coherence and high risk for depression, 618
in extended wakefulness in seasonal affective disorder, 610
first-night data for sleep of depressed inpatients, 626
regional brain activity in social phobia, 85
sleep EEG coherence in depressed children and adolescents, 338
Electromyography
in schizophrenia, 991
Entorhinal cortex
dopamine levels in schizophrenia, 361
in frontotemporal dementia and Alzheimer disease, 1056
pre-alpha cell clusters in schizophrenia, 937
Environmental factors
in schizophrenia, 210
stimuli affecting locomotor behavior in developing rats, 864
Errata
Bremner article (2000;47:96–106), 850
Mathalon article (2000;47:413–427), 1092
McGlashan article (1999;46:899–907), 473
Estradiol
and tryptophan hydroxylase regulation in dorsal raphe of macaques, 562
Ethanol withdrawal
and moxonidine affecting acoustic startle response in rats, 874
Ethics
and placebo use in clinical trials, 687-ed, 707
NIMH perspective on, 689-ed
Ethnicity
and sleep duration, 921
Event-related potentials
auditory
and executive control in schizophrenia, 51
novel stimuli affecting, in posttraumatic stress disorder, 880
P50 amplitude in adult attention-deficit disorder, 969
reduction of P300 amplitude as trait of schizophrenia, 434
schizophrenia illness duration related to P300 amplitude reduction, 413
and schizophrenic risk factors, 402
in siblings of schizophrenic probands, 380
suppression of P50 in schizophrenia, 463
visual
in alcoholism and frontolimbic brain pathology, 1064
and antisaccadic tasks in schizophrenia, 978
Excitability
and blink reflex in schizophrenia, 43
Executive functioning
control in schizophrenia, 51
ketamine affecting, 137
Eye movements
in anxiety, 112
in families with schizophrenia, 231, 391

Family
carbon dioxide challenge test in relatives of panic disorder patients, 830
eye movements in families with schizophrenia, 231, 391
P300 abnormalities in siblings of schizophrenic probands, 380
status and schizotypy affecting event-related potentials, 402
Family history
and lithium response in bipolar disorder, 1034
Fatty acids
metabolism in schizophrenia, 8

polyunsaturated, affecting proinflammatory cytokines in stress, 910
Fearful temperament
and brain corticotropin-releasing hormone activity in monkeys, 579
Fenfluramine challenge
effects in MDMA users, 127
and PET study of borderline personality disorder, 540
Flashbacks
induced by cholecystokinin tetrapeptide, 107
Flow cytometry
cellular responses to social deprivation in monkeys, 119
Fluoxetine
combined with pindolol, 1050
preventing neurotoxicity of NMDA receptor antagonists, 836
Fluvoxamine
trial in pathologic gambling, 813
Frontal areas
and abstraction in schizophrenia, 34
and executive control in schizophrenia, 51
Frontal cortex
and performance in Wisconsin Card Sorting Test, 137
Frontal lobes
in frontotemporal dementia and Alzheimer disease, 1056
hypometabolism in alcoholism, 1064
phosphodiesters in schizophrenia, 954

GABA receptor
allopregnanolone in cerebral cortex affected by olanzapine, 1000
topiramate affecting, in bipolar disorders, 1025
Gambling, pathologic
fluvoxamine/placebo trial in, 813
Gating
sensorimotor
neuroleptic drugs affecting, 61
and prepulse inhibition in schizophrenia, 662
sensory, auditory
in families of schizophrenic people, 231
and P50 suppression in schizophrenia, 463
Gender
and hippocampal volume in major depression, 1087
learning disabilities in low birthweight boys, 490
and sleep duration, 921
Genetics
in Alzheimer disease, 183
in bipolar disorder, 171-ed
catechol-*O*-methyltransferase alleles in prepubertal bipolarity, 605
molecular mechanisms in learning and memory, 200
in obsessive–compulsive disorders, 296
psychiatric disorders as oligogenic diseases, 240
psychiatric pharmacogenetics, 252
in schizophrenia, 171-ed, 210
serotonin transporter genotypes in alcoholism, 643
susceptibility genes in schizophrenia, 221
susceptibility loci for anorexia nervosa, 794
transmission of risk factors among relatives of schizophrenic people, 231
Wolfram syndrome locus mutations, 787
Glutamate
cingulate cortex levels in depression, 305
receptors in schizophrenic thalamus, 22
Glutamine
cerebrospinal fluid levels in depression, 586
Glycine
and amino acid levels in cerebrospinal fluid, 450
Growth hormone
nocturnal secretion in adolescence, 594

Habituation
and prepulse inhibition in schizophrenia, 662
and startle reactivity in rats affected by environmental stimuli, 864
Heart rate
measurements in social phobia, 85
and neuropeptide Y levels in posttraumatic stress disorder, 526
Heat shock protein 70
induction prevented by fluoxetine, 836
Heroin dependence
buprenorphine maintenance treatment in, 1072
with disulfiram for cocaine dependence, 1080
Hippocampus
abnormalities in families of schizophrenic people, 231
in Alzheimer disease, 557
amygdalo-hippocampal complex in violent behavior, 928
benzodiazepine receptor binding in panic disorder, 96
in frontotemporal dementia and Alzheimer disease, 1056
neurogenesis in rat dentate gyrus after electroconvulsive seizures, 1043
pindolol affecting firing of serotonergic neurons, 1050
volume in major depression, 1087
HIV infection
protease inhibitors affecting trazodone metabolism by CYP3A, 655
Homovanillic acid
plasma levels in prodromal phase of schizophrenia, 428
Hybridization in situ
glutamate receptors in schizophrenic thalamus, 22

Illumination
and sleep duration, 921
Imidazoline antagonist
and acoustic startle response in ethanol withdrawal in rats, 874
Immune system
decreased ICAM levels in schizophrenia, 29
social deprivation affecting, in monkeys, 119
Immunocytochemistry
dopamine in entorhinal cortex in schizophrenia, 361
Impulsivity
in borderline personality disorder
and fenfluramine challenge, 540
and serotonergic blunting in traumatized patients, 548
and fluvoxamine in pathologic gambling, 813

Indinavir
and trazodone metabolism by CYP3A, 655
Infants
citalopram in breast milk affecting, 164
Intelligence
IQ deficits aassociated with neurologic soft signs, 71
Interferon γ
production in stress affected by fatty acids, 910
Interleukins
production in stress affected by fatty acids, 910
Isolation
in early life, affecting development in rats, 864

Ketamine
antidepressant effects of, 351
and executive cognitive functions, 137
Ketoconazole
and trazodone metabolism by CYP3A, 655

Lactate
responses of domestic violence perpetrators, 804
Learning
disability in low birthweight boys, 490
molecular and cellular mechanisms in, 200
Light therapy
and circadian variations in forced desynchronization, 355
Lighting
and sleep duration, 921
Lithium
in bipolar disorder, responses related to family history, 1034
Locomotor activity
early environmental stimuli affecting, in rats, 864
Lysergic acid diethylamide
preventing dizocilpine neurotoxicity, 836

Magnetic resonance imaging
functional, and amygdala responses in posttraumatic stress disorder, 769
hippocampal
in Alzheimer disease, 557
atrophy in frontotemporal dementia and Alzheimer disease, 1056
volume in major depression, 1087
Magnetic resonance spectroscopy
brain metabolites in depression, 305
brain regions in violent behavior, 804
cerebrospinal fluid glutamine levels in depression, 586
dorsolateral prefrontal *N*-acetyl-aspartate levels in bipolar disorder, 475
frontal lobe phosphodiesters in schizophrenia, 954
in pediatric obsessive–compulsive disorder, 174
Magnetic stimulation, transcranial
inactive forms of, 325
in major depressive disorder, 314
randomized clinical trial of, 332
Mania and depression. *See* Bipolar disorder
Maternal behavior
after prepartum ultramild stress in mice, 858
Medroxyprogesterone acetate
and tryptophan hydroxylase regulation in dorsal raphe of macaques, 562
Membrane physiology
in schizophrenia, 8
Memory
and abstraction in schizophrenia, 34
molecular and cellular mechanisms in, 200
Mental impairment
and violent behavior, 928
Metabolism
dexamethasone, in dexamethasone suppression tests, 677
fatty acids, in schizophrenia, 8
frontal lobe hypometabolism in alcoholism, 1064
phospholipid, in schizophrenia, 8, 954
trazodone, by CYP3A, 655
N-Methyl-D-aspartate (NMDA)
antagonists with antidepressant activity, 351
neurotoxicity of receptor antagonists prevented by fluoxetine, 836
receptor function affected by glycine, 450
receptors involved in executive cognitive functions, 137
3,4-Methylenedioxymethamphetamine (MDMA)
long-lasting effects on serotonin system, 127
Midbrain
serotonin transporter in depressed suicide victims, 1015
Military medicine
posttraumatic stress disorder
amygdala responses in, 769
attentional allocation in, 880
neuropeptide Y levels in, 526
and sleep in elderly veterans, 520
survival training
endocrine responses in, 891
neuropeptide Y levels in, 902
Mood
circadian variations in forced desynchronization, 355
tryptophan depletion affecting, in bulimia nervosa, 151
Mood disorders
and effects of noise intensity, 634
neurokinin-1 receptors in, 80
Mortality
social deprivation affecting, in monkeys, 119
Moxonidine
and acoustic startle response in ethanol withdrawal in rats, 874
Muscle biopsy
in schizophrenia, 991

N2 amplitude
and NoGo tasks in schizophrenia, 51
N400 amplitude
in relatives of schizophrenic people, 402
National Depressive and Manic-Depressive Association, 692
National Institute of Mental Health
perspective on placebo use, 689-ed
perspective on schizophrenia research, 1

Negative symptoms
and dopamine and serotonin transporters in schizophrenia, 371
and ICAM levels in serum, 29
Nelfinavir
and trazodone metabolism by CYP3A, 655
Neurodevelopment
pre-alpha cell clusters in entorhinal cortex in schizophrenia, 937
Neuroendocrine system
responses to military survival training, 891
Neurofibromatosis
and mechanisms in cognitive function, 200
Neurogenesis
in rat dentate gyrus after electroconvulsive seizures, 1043
Neuroimaging
studies of obsessive–compulsive disorder, 168-ed
Neurokinin-1
receptors in mood disorders or schizophrenia, 80
Neuroleptics. *See* Antipsychotic drugs
Neurologic soft signs
in low birthweight children, 71
Neuropeptide Y levels
in military survival training, 902
in posttraumatic stress disorder, 526
Neuropil space
in schizophrenia, 681-corr
Neuropsychiatric disorders
pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS), 851
Neurosteroids
allopregnanolone in cerebral cortex affected by olanzapine, 1000
Nicotinic receptors
abnormalities in families of schizophrenic people, 231
NoGo tasks
and executive control in schizophrenia, 51
Noise intensity
and affective disorders, 634
Norepinephrine
reboxetine as reuptake inhibitor, 818
transporter binding by paroxetine, 842
Novel stimuli
and attentional allocation in posttraumatic stress disorder, 880
Nystagmus, vestibular
in anxiety, 112

Obsessive–compulsive disorders
compared to Sydenham chorea, 851
neurobiology of, 296
neuroimaging studies, 168-ed
pediatric, spectroscopic imaging in, 174
Olanzapine
and allopregnanolone in cerebral cortex, 1000
and slow-wave sleep, 468
Oligonucleotide synthesis
for metabotropic glutamate receptor studies, 22
Omega-3 fatty acids
in schizophrenia, 8
Opioid dependence
buprenorphine maintenance treatment in, 1072
with disulfiram for cocaine dependence, 1080
Orientation
and spatial perception in anxiety, 112

P3 amplitude
and NoGo tasks in schizophrenia, 51
P50 amplitude
in attention-deficit disorder in adults, 969
suppression deficits in schizophrenia, 463
P300 amplitude
abnormalities in siblings of schizophrenic probands, 380
in alcoholism and frontolimbic brain pathology, 1064
and illness duration in schizophrenia, 413
novel stimuli affecting, in posttraumatic stress disorder, 880
in relatives of schizophrenic people, 402
as trait or state marker in schizophrenia, 434
Pain
and cortisol levels in aged subjects, 144
Panic
benzodiazepine receptor binding in, 96
and carbon dioxide challenge test in relatives of patients, 830
induced by cholecystokinin tetrapeptide, 107
lactate-induced, and domestic violence, 804
Paroxetine
binding to norepinephrine transporter, 842
platelet serotonin content affecting responses in depression, 846-corr
Perceptual anomalies
and gating deficits in schizophrenia, 463
PET studies
and fenfluramine challenge in borderline personality disorder, 540
Pharmacogenetics
of antipsychotic response, 252
Phencyclidine (PCP)
neurotoxicity prevented by fluoxetine, 836
Phobic disorders
brain and autonomic function in social phobia, 85
Phosphodiesters
in frontal lobe in schizophrenia, 954
Phospholipids
metabolism in schizophrenia, 8, 954
Pindolol
combined with fluoxetine, 1050
Placebos in clinical trials, 687-ed
and active control groups, 693
additive drug and placebo effects in depression, 733
in assessment of psychiatric drugs, 699
in bipolar illness, 727
in acute mania, 748
in maintenance treatment, 756
designs for reduction of, 724
ethical issues in, 707

NIMH perspective on, 689-ed
in pathologic gambling, 813
statistical issues in, 717
in unipolar major depression, 736
current status of, 745
Platelets
serotonin content affecting responses to paroxetine in depression, 846-corr
Polysomnography. *See* Sleep
Positive syndrome
neuroleptics affecting sensorimotor gating in, 61
Postmortem studies
dopamine in entorhinal cortex in schizophrenia, 361
Posttraumatic stress disorder
amygdala responses in, 769
attentional allocation in, 880
aversive conditioning in, 512
and endocrine responses to survival training, 891
neuropeptide Y levels in, 526
in survival training, 891
response to cholecystokinin tetrapeptide in, 107
and sleep in elderly veterans, 520
Postural sway
in children, and risk for alcoholism, 501
Precuneus
benzodiazepine receptor binding in panic disorder, 96
Prefrontal cortex
benzodiazepine receptor binding in panic disorder, 96
Pregnancy
and prepartum ultramild stress in mice, 858
Prepulse inhibition of startle
and antipsychoticlike activity of amoxapine, 670
and environmental stimuli affecting behavior in rats, 864
impairment in schizophrenia, 662
neuroleptics affecting, 61
Presenilin genes
in Alzheimer disease, 183
Problem solving
and abstraction in schizophrenia, 34
Prodromal phase of schizophrenia
plasma homovanillic acid in, 428
Progesterone
and tryptophan hydroxylase regulation in dorsal raphe of macaques, 562
Prolactin
responses to challenge test in traumatized borderline personality patients, 548
serum levels in MDMA users, 127
Prostaglandins
activity in schizophrenia, 8
Protease inhibitors
and trazodone metabolism by CYP3A, 655
Psychotropic drugs
evaluation with placebo control groups, 699

Rage
lactate-induced, and domestic violence, 804
Randomized controlled trials
assessment of psychiatric drugs in, 699
placebos used in, 687-ed. *See also* Placebos in clinical trials and active control groups, 693
Reboxetine
as norepinephrine reuptake inhibitor, 818
Research
brain function after vagus nerve stimulation, 287
clinical trials in. *See* Clinical trials
eating disorders, 775
neuroimaging studies of obsessive–compulsive disorder, 168-ed
NIMH perspective on schizophrenia, 1
and placebos in clinical trials, 687-ed, 707
search for schizophrenia susceptibility genes, 221
Risk factors
childhood postural sway and alcoholism development, 501
DHEA-S levels in Alzheimer disease, 161
environmental, in schizophrenia, 210
learning disabilities in low birthweight boys, 490
sleep EEG coherence abnormalities in depression, 618
transmission among relatives of schizophrenic people, 231
Ritonavir
and trazodone metabolism by CYP3A, 655

Saccades
contingent negative variation in schizophrenia, 978
in families with schizophrenia, 391
Sauinavir
and trazodone metabolism by CYP3A, 655
Schizophrenia
abstraction and working memory in, 34
antisaccadic tasks in, 978
blink reflex in, 43
cognitive function in geriatric patients, 962
decreased ICAM levels in, 29
and dopamine levels in entorhinal cortex, 361
dopamine transporters in, 371
environmental factors in, 210
executive control in, 51
and eye movement abnormalities in families, 231, 391
fatty acid metabolism in, 8
genetic factors in, 171-ed, 210
glutamate receptors in thalamus, 22
homovanillic acid plasma levels in prodromal phase, 428
illness duration affecting P300 amplitude, 413
and mechanisms in cognitive function, 200
neurokinin-1 receptors in, 80
NIMH perspective on research, 1
as oligogenic disease, 240
overlapping linkage with bipolar disorder, 245
P50 suppression deficits in, 463
and P300 abnormalities in siblings, 380
P300 amplitude as trait or state marker in, 434
pharmacogenetics of clozapine response, 252
phosphodiesters in frontal lobe, 954
pre-alpha cell clusters in entorhinal cortex, 937
prepulse inhibition in, 662
neuroleptics affecting, 61

reduced interneuronal space in, 681-corr
serotonin transporters in, 371
susceptibility genes, 221
thalamic neuron numbers in, 944
transmission of risk factors among relatives, 231
Schizotypy
in relatives of schizophrenic people, 402
Seasonal affective disorder
circadian rhythms in, 355
serotonin transporter availability in, 482
sleepiness and waking EEG in, 610
Seasonality
schizophrenic births, 210
serotonin transporter binding sites, 158
Secretases
in Alzheimer disease, 183
Self-elicitation
and blink reflex in schizophrenia, 43
Self-reports
of perceptual anomalies in schizophrenia, 463
Semantic processing
in relatives of schizophrenic people, 402
Sensorimotor gating
neuroleptic drugs affecting, 61
and prepulse inhibition in schizophrenia, 662
Sensory gating, auditory
in families of schizophrenic people, 231
and P50 suppression in schizophrenia, 463
Serotonin
and bulimia nervosa pathophysiology, 151
long-lasting impairment in MDMA users, 127
neural function affected by ovarian hormones in monkeys, 562
olanzapine affecting 5-HT_{2C} receptors, 468
receptors affected by traumatic stress in borderline personality patients, 548
responses to fenfluramine challenge in borderline personality disorder, 540
reuptake inhibitors
combined with pindolol, 1050
and neurotoxicity of NMDA receptor antagonists, 836
in pathologic gambling, 813
role in obsessive–compulsive disorders, 296
transporters
availability in seasonal affective disorder, 482
in midbrain of depressed suicide victims, 1015
in schizophrenia, 371
seasonal variation of binding sites, 158
type related to alcohol neurotoxicity, 643
Sleep
EEG coherence abnormalities
in depressed children and adolescents, 338
and high risk for depression, 618
factors affecting duration of, 921
first-night data in depressed inpatients, 626
nocturnal growth hormone secretion in adolescence, 594
olanzapine affecting, 468
and posttraumatic stress disorder in elderly veterans, 520
Sleepiness
in seasonal affective disorder, 610
Smooth pursuit
in families with schizophrenia, 391
Social deprivation
affecting survival and immunity in monkeys, 119
Social phobia
brain and autonomic function in, 85
Spatial perception
in anxiety, 112
SPECT studies
benzodiazepine receptor binding in panic disorder, 96
dopamine and serotonin transporters in schizophrenia, 371
in seasonal affective disorder, 482
seasonal variation of serotonin transporter binding, 158
serotonin transporter genotypes in alcoholism, 643
Spectral analysis of sleep EEG
coherence abnormalities and high risk for depression, 618
for depressed inpatients, 626
Spectroscopic imaging. *See* Magnetic resonance spectroscopy
Startle response
and antipsychoticlike effects of amoxapine, 670
and blink reflex in schizophrenia, 43
and environmental stimuli affecting behavior in rats, 864
in ethanol withdrawal in rats, moxonidine affecting, 874
glycine affecting, 450
and prepulse inhibition in schizophrenia, 662
neuroleptics affecting, 61
Stochastic resonance
and effects of noise on affective disorders, 634
Streptococcus
pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS), 851
Stress
behavior after prepartum ultramild stress in mice, 858
posttraumatic disorder in. *See* Posttraumatic stress disorder
and proinflammatory cytokines affected by polyunsaturated fatty acids, 910
Substance P
receptors in mood disorders or schizophrenia, 80
Survival training, military
hormone responses to, 891
plasma neuropeptide Y levels in, 891
Sydenham chorea
diagnostic criteria for, 851
Synaptic plasticity
mechanisms in, 200

Tamoxifen
and tryptophan hydroxylase regulation in dorsal raphe of macaques, 562
Temperature of body
and mood variations in winter depression, 355
Temporal lobe, medial
in frontotemporal dementia and Alzheimer disease, 1056
role in violent behavior, 928
Testosterone
and cognition in elderly men, 650

reduced levels after survival training, 891
Thalamus
glutamate receptors in schizophrenia, 22
neuron numbers in schizophrenia, 944
in pediatric obsessive–compulsive disorder, 174
Thyroid hormones
reduced levels after survival training, 891
Topiramate
in bipolar disorders, 1025
Tourette syndrome
compared to Sydenham chorea, 851
Trazodone
metabolism by CYP3A, 655
Tryptophan
depletion in bulimia nervosa, 151
Tryptophan hydroxylase
regulation in dorsal raphe of macaques, 562
Tumor necrosis factor-α
production in stress affected by fatty acids, 910
Tyrosine hydroxylase
immunoreactive axon density in schizophrenia, 361

Ultradian rhythms
rapid cycling in childhood and adolescent bipolarity, 605
sleep EEG coherence in depressed children and adolescents, 338

Vagus nerve
stimulation for treatment-resistant depression, 273-ed
historical review of, 287
multicenter study of, 276
Vestibulo-ocular reflex
in anxiety, 112
Veterans. *See* Military medicine
Violent behavior
and lactate-induced rage and panic, 804
prefrontal cortex and amygdalo-hippocampal complex in, 928
Visual event-related potentials
in alcoholism and frontolimbic brain pathology, 1064
and antisaccadic tasks in schizophrenia, 978

Wakefulness
in seasonal affective disorder, 610
Weight loss
from topiramate in bipolar disorders, 1025
Wisconsin Card Sorting Test
and abstraction in schizophrenia, 34
ketamine affecting performance in, 137
Wolfram syndrome
locus mutations and psychiatric illness, 787
Working memory
and abstraction in schizophrenia, 34